Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07004439

A Post-market Registry to Assess Safety and Performance of RefluxStop™ in the Treatment of GERD in General Hospital Practice

A post-market retrospective and prospective, open label, multicenter, single-arm registry study using standard clinical procedures to record available and/or new data to evaluate the safety and performance of RefluxStop™ for the treatment of subjects suffering from GERD.

Following surgery, patients will have follow-ups visits at 3 and 6 months and annually up to 7 years.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Klinikum Friedrichshafen GmbH, Friedrichshafen, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing and able to provide informed consent and to participate in the registry study;
  • Age ≥ 18 years or according to local legal age of adulthood at the location of the test site if older;
  • Documented GERD present for ≥ 6 months. Typical symptoms are defined as heartburn;
  • 24-hour pH or impedance pH monitoring proven GERD with pH measurement, off PPI therapy for at least 7 days prior to testing. (Total distal esophageal pH must be < 4 for ≥ 4.5% of total time during a 24-hour monitoring) and/or total reflux episodes >55 or weekly acid >26 for > 5 seconds, all measured 5 cm above LES);
  • Suitable to undergo general anaesthesia and is a suitable laparoscopic surgery candidate as determined by the investigator.

Exclusion criteria

  • Hiatal Hernia larger than 8 cm;
  • Known presence of delayed gastric emptying, if no other cause for acid reflux could be diagnosed. Patients with substantially weak peristalsis (manometry DCI value 100-200) in esophagus measured during manometry would continue the simplified contrast swallow x-ray to perform a simplified two-hour gastric emptying contrast swallow
  • History of bariatric surgery wherein the stomach fundus has been extirpated;
  • Female subjects who are pregnant;
  • Known sensitivity or allergies to silicone materials;
  • Intraoperative findings determined by the investigator that may result in unfavorable conduct of the registry procedure (as outlined in the IFU);
  • Subjects that are unable to comply with the registry requirements (for example due to major psychiatric disorder or are considered otherwise unsuitable for participation in the clinical investigation according to the investigator's judgement).

Treatment and study plan

RefluxStop™ implantation

Device

Standard surgical technique for implantation RefluxStop™, as described in the Instructions for Use

Primary outcomes

  1. Reduction of Patient Reported Outcome - Side effects (PROS)

    Time frame: 1 year

    Patient Reported Outcome - Side effects (PROS) combine the established side effects: Dysphagia, Odynophagia, Inability to Belch, Inability to Vomit, and worsened Gas bloating, compared to baseline

Secondary outcomes

  1. Incidence of safety events

    Time frame: 3 and 6 months and years 1 to 7

    Safety events include: SADEs, SAEs, ADEs, procedure-related or unknown AEs and DDs

  2. Reduction of Patient Reported Outcome - Side effects (PROS)

    Time frame: 6 months and years 2 to 7

    Patient Reported Outcome - Side effects (PROS) combine the established side effects: Dysphagia, Odynophagia, Inability to Belch, Inability to Vomit, and worsened Gas bloating, compared to baseline

Sponsors and collaborators

Lead sponsor

Implantica CE Reflux Ltd.

Industry

Registry information

Official study title

A Post-market Registry Study Based on Standard Clinical Care to Assess Safety and Performance of RefluxStop™ in the Treatment of Gastroesophageal Reflux Disease (GERD) in General Hospital Practice

Acronym: RESTORE500

Important dates

Study start
2025
Primary completion
2029
Study completion
2035
First posted
Jun 4, 2025
Registry last updated
Jun 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.